Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: cardiovascular, muscle
- Who it enrolls
- age 50 Years to no upper limit; excludes diabetes; BMI ≥30 required; conditions: Obesity Prevention; Sarcopenia in Elderly; Cardiovascular Function; GLP - 1
- Interventions
- Tirzepatide
- Conditions
- Obesity Prevention; Sarcopenia in Elderly; Cardiovascular Function; GLP - 1; Weight Loss
- Phase and size
- Phase 2 · 20 participants
- Dates
- Start 2026-04-01
Primary completion 2027-04-01 - Sponsor
- The University of Texas Health Science Center at San Antonio (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Appendicular lean muscle mass6 months
- Muscle Strength6 months
- Lower Extremity Functional Capacity6 months
02Eligibility
Who can take part
Inclusion Criteria * Men and postmenopausal women aged 50 years or older. * Body Mass Index (BMI) ≥30 kg/m². * Untreated HbA1c \<6.5% at baseline. * Willingness and ability to comply with all study procedures, including fasting requirements for certain visits. * Able to provide informed consent and participate in all study assessments. Exclusion Criteria * Active diagnosis of type 2 diabetes mellitus (T2DM), defined by active use of glucose-lowering medications or hemoglobin A1c ≥ 6.5%. * Body Mass Index (BMI) ≥ 40 kg/m². * Moderate to severe gastroesophageal reflux disease based on patient history. * Inability to comply with the treatment protocol or to understand the consent form. * Chronic Kidney Disease (CKD) Stage 4. * Aspartate aminotransferase (AST) \> 33 U/L or alanine aminotransferase (ALT) \> 36 U/L. * Active pregnancy. * Personal or family history of medullary thyroid carcinoma. * Personal or family history of multiple endocrine neoplasia type 2 syndrome. * Personal history of gastroparesis. * Personal history of diabetic retinopathy. * Known serious hypersensitivity, including anaphylaxis and angioedema, to Tirzepatide or any of its excipients. * Known serious hypersensitivity, including anaphylaxis and angioedema, to any GLP-1 receptor agonist class of therapies. * Concomitant treatment with GLP-1 receptor agonist therapy
03Change log
Registry changes
No changes recorded since the trial was added.